-
Mashup Score: 2Camrelizumab/Rivoceranib Maintains Survival Benefits in uHCC - 2 day(s) ago
The combination of camrelizumab and rivoceranib significantly improved survival rates in patients with unresectable liver cancer compared with standard treatment.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Isatuximab Plus VRd Earns FDA Priority Review in NDMM - 2 day(s) ago
The FDA has set a target action date of September 27, 2024, for a decision on the supplemental biologics license application of isatuximab plus bortezomib, lenalidomide, and dexamethasone.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Scott T. Tagawa, MD, MS, FACP, FASCO, highlights a key difference between oral androgen receptor inhibitor drugs and therapeutic radionuclides for the treatment of prostate cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1ADCs Change the Game for Cancer Treatment - 2 day(s) ago
In part 2 of our 3-part series, antibody-drug conjugates like enfortumab vedotin and tisotumab vedotin offer novel options for difficult-to-treat tumors.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
In an interview with Targeted Oncology, Paolo Ghia, MD, PhD, discussed the 5-year results from the CAPTIVATE study in chronic lymphocytic leukemia and/or small lymphocytic lymphoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Estrogen Therapy Alone Raises Ovarian/Endometrial Cancer Risk in Postmenopausal Women After Hysterectomy - 2 day(s) ago
CEE therapy alone in postmenopausal women after hysterectomy was linked to a substantial increase in ovarian cancer incidence and mortality.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the specific patient subgroups for whom autologous transplant remains the best course of action for.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
While Dato-DXd numerically improved overall survival for patients with non-small cell lung cancer, the data did not show statistical significance. However, a clinically meaningful benefit was observed in a subgroup of patients.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 16FDA Approves Liso-Cel in Mantle Cell Lymphoma - 2 day(s) ago
The FDA has approved the CAR T-cell therapy liso-cel for the treatment of patients with mantle cell lymphoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
The FDA has approved a phase 1, first-in-human trial to evaluate the safety and potential effectiveness of ACTM-838, a novel immunotherapy drug for advanced solid tumors.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Camrelizumab+rivoceranib sustained favorable long-term survival results vs sorafenib when used in the frontline for patients with unresectable hepatocellular carcinoma, according to findings from the phase 3 CARES-310 study. #HCC https://t.co/wGILUCkxZl